Pharmagreen Biotech, (OTC PINKS: AITGD), a cannabis biotech company focused on producing cannabis starter plantlets through its proprietary tissue culture process is pleased to announce that its wholly owned Canadian subsidiary, WFS Pharmagreen Inc., is currently completing its pre-construction phase of its 62,000 square foot cannabis biotech complex. WFS Pharmagreen has filed for regulatory approval from Health Canada for the cannabis biotech complex. The facility will supply over ten million cannabis tissue culture starter plantlets on an annual basis, operating at full capacity. The company’s plan is reach over ninety percent of production capacity in the first year. Ten million starter plantlets produced at an average sale price of $8 US per plantlet would generate eighty million US dollars in annual gross revenues.
Read more
Pharmagreen Biotech, Inc. Strategic Relationship with Alliance Growers Inc.
